AU2022290378A1 - Autotaxin (atx) inhibitor for the treatment of pancreatic cancer - Google Patents

Autotaxin (atx) inhibitor for the treatment of pancreatic cancer Download PDF

Info

Publication number
AU2022290378A1
AU2022290378A1 AU2022290378A AU2022290378A AU2022290378A1 AU 2022290378 A1 AU2022290378 A1 AU 2022290378A1 AU 2022290378 A AU2022290378 A AU 2022290378A AU 2022290378 A AU2022290378 A AU 2022290378A AU 2022290378 A1 AU2022290378 A1 AU 2022290378A1
Authority
AU
Australia
Prior art keywords
compound
pancreatic cancer
salt
treatment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022290378A
Other languages
English (en)
Inventor
Marcel DEKEN
Zoë JOHNSON
Michael LAHN
Davide MELISI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionctura BV
Original Assignee
Ionctura BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionctura BV filed Critical Ionctura BV
Publication of AU2022290378A1 publication Critical patent/AU2022290378A1/en
Assigned to iOnctura BV reassignment iOnctura BV Request for Assignment Assignors: IONCTURA SA
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022290378A 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer Pending AU2022290378A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2108245.8 2021-06-09
GBGB2108245.8A GB202108245D0 (en) 2021-06-09 2021-06-09 Methods of treatment
PCT/EP2022/065562 WO2022258693A1 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
AU2022290378A1 true AU2022290378A1 (en) 2024-01-04

Family

ID=76838834

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022290378A Pending AU2022290378A1 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer

Country Status (9)

Country Link
US (1) US20250057820A1 (https=)
EP (1) EP4351563A1 (https=)
JP (1) JP2024522135A (https=)
CN (1) CN117295496A (https=)
AU (1) AU2022290378A1 (https=)
CA (1) CA3218103A1 (https=)
GB (1) GB202108245D0 (https=)
MX (1) MX2023014637A (https=)
WO (1) WO2022258693A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502020D0 (en) * 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
JP2024511836A (ja) * 2021-03-29 2024-03-15 アイオンクチュラ・ソシエテ・アノニム 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤

Also Published As

Publication number Publication date
CN117295496A (zh) 2023-12-26
CA3218103A1 (en) 2022-12-15
GB202108245D0 (en) 2021-07-21
US20250057820A1 (en) 2025-02-20
JP2024522135A (ja) 2024-06-11
EP4351563A1 (en) 2024-04-17
MX2023014637A (es) 2024-01-31
WO2022258693A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
AU2012321110B2 (en) Combination treatment
US20160193211A1 (en) Combinations of a btk inhibitor and fluorouracil for treating cancers
CN103533940A (zh) 治疗晚期实体瘤的方法
TW201625243A (zh) 用於治療黑素瘤之藥物組合
US20240216385A1 (en) A pi3k-delta inhibitor for the treatment of pancreatic cancer
Nelson et al. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer
US20250057820A1 (en) Autotaxin (atx) inhibitor for the treatment of pancreatic cancer
WO2021140478A1 (en) Combination therapy for treating cancer
US20210205272A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
WO2021175432A1 (en) Method for administration of an anti cancer agent
RU2519199C2 (ru) Противоопухолевый агент, набор и способ лечения рака
CN102939086B (zh) 胃癌的治疗方法
JP2005255643A (ja) 抗腫瘍効果増強方法および抗腫瘍効果増強剤
US11382892B2 (en) Method for administration
WO2024121861A1 (en) Egfr inhibitor for the treatment of head and neck cancer
WO2024246824A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
HK40103578A (en) Egfr inhibitor for the treatment of head and neck cancer
HK40103578B (en) Egfr inhibitor for the treatment of head and neck cancer
NZ625611B2 (en) Combination treatment of cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: IONCTURA BV

Free format text: FORMER APPLICANT(S): IONCTURA SA